Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Provectus Updates Shareholders in Its Annual CEO Letter
Tuesday July 8, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, provides shareholders with an update on its corporate accomplishments, clinical progress and business development efforts during 2013, and shares as well as insights on upcoming plans and milestones for 2014.
Dear Shareholders,
Since our last letter, Provectus has gone through significant changes on multiple levels. The past several months have placed us in a much different, and stronger position than we had been previously. This is true for our regulatory path, our scientific situation, our corporate structure, our financial strength and our commercial prospects. This is an ideal time to review where we have been and to discuss where we are going in a continuing effort to be as transparent as possible.
The most prominent development recently was the information obtained from our application for Breakthrough Therapy Designation (BTD) to the FDA for PV-10 in the treatment of locally advanced cutaneous melanoma. In the interest of transparency, we announced every step of the BTD process, including the date of submission of our application and the release of the FDA's response letter. While the immediate result was not what we had hoped, we are enthusiastic about the FDA's statement that "The preliminary clinical data provided in your request for Breakthrough Therapy designation are indicative of drug activity in the treatment of local, satellite or in-transit recurrence of malignant melanoma." This communication between the FDA and Provectus has proved quite valuable in discerning our regulatory path forward.
PHASE 2 RESULTS
Our development plans for PV-10 stem from the results of our phase 2 study. In that trial, tumors were no longer detectable in 50% of patients with locally advanced cutaneous melanoma who had all of their existing lesions injected. Results from these patients support the potential of PV-10 as a single agent, and provide rationale for a phase 3 randomized controlled trial in patients with unresectable, locally advanced cutaneous melanoma.
Top-line results from the phase 2 trial have been posted on clinicaltrials.gov, for the study entitled "Phase 2 study of Intralesional PV-10 for Metastatic Melanoma," [NCT00521053]. http://clinicaltrials.gov/ct2/show/NCT00521053?term=NCT00521053&rank=1.
When we completed data collection two years ago, we knew we had a promising oncolytic agent with consistent response in injected tumors, but we also had intriguing data on the bystander effect that implicated a secondary immunologic mechanism of action. At that time, we had no agreement with FDA on a proposed indication, no phase 3 clinical trial drug supply and too many variables for design of an efficient phase 3 trial.
The gap between completion of the data collection and the outlining of our plans in the conference call of June 19, 2014, stemmed from these regulatory hurdles and from our determination to properly structure a study where we could adequately predict the outcome. When preparing for phase 3 testing it is critical to understand exactly what your drug is doing, which patients are most likely to benefit, what other options these patients have, and what endpoint or endpoints would be most convincing for government agencies to approve the drug.
After presenting data from our phase 2 study in a Type C meeting last December and in our BTD application submitted this spring, the FDA confirmed that locally advanced cutaneous melanoma is a serious condition. With this agreement on indication, our subgroup analysis of data from these patients in the phase 2 trial, and an appropriate phase 3 supply chain for our drug, we are now in a position to embark on the phase 3 study.
PHASE 3 OUTLINE FOR MELANOMA
The planned phase 3 study will assess response to intralesional PV-10 vs. that of systemic chemotherapy in patients with disease confined to cutaneous and subcutaneous sites. These patients will have failed or be ineligible for systemic immunotherapy. Patients who would be eligible have extremely limited options, consisting principally of systemic chemotherapy (such as DTIC or temozolomide) or a clinical trial.
The primary endpoint of the study is progression-free survival (PFS) assessed using standard RECIST 1.1 criteria. Secondary endpoints are complete response rate and overall survival. Progression-free survival and overall survival are standard endpoints for oncology approvals. With these assessment methods and endpoints we're following what the FDA has suggested to document the clinical benefit to patients after intralesional injection. And, we'll measure patient reported outcomes to better characterize the relationship between complete response and symptoms of locally advanced cutaneous melanoma, such as pain and bleeding.
Based on estimated effect size derived from the phase 2 data and literature data for the comparator drugs, we project that approximately 210 patients will be needed for the study, with 2 to 1 randomization. Meetings with scientific advisors, investigators and advocates in the field have led us to expect a starting date for the phase 3 study sometime in the second half of 2014. Based on our experience enrolling similar patients in the mechanism of action study we're sponsoring at Moffitt Cancer Center, we are confident about enrolling patients within an 18-month target, starting with the eight existing PV-10 sites, which are currently enrolling melanoma patients, and expanding to additional sites as the study proceeds.
We have recently signed agreements with two manufacturers to supply us with clinical-quality PV-10, and we now have sufficient quantities of PV-10 available to commence this phase 3 trial and undertake our other development activities. To assure smooth execution of the study we've lined up specialty contract research organizations (CROs) and other service providers with expertise in clinical operations and integrated data management. As is standard in our industry, this includes a full-service, international CRO who will coordinate the global efforts of this team of specialists.
We'll work with this team to establish an independent Clinical Trial Data Monitoring Committee (DMC). The FDA states "A clinical trial DMC is a group of individuals with pertinent expertise that reviews on a regular basis accumulating data from one or more ongoing clinical trials. The DMC advises the sponsor regarding the continuing safety of trial subjects and those yet to be recruited to the trial, as well as the continuing validity and scientific merit of the trial." The DMC will ensure that our study provides patients with maximum possible safety while protecting the scientific validity and integrity of the data we gather.
THE INTRALESIONAL APPROACH TO TREATMENT
Provectus is not alone in advocating for an intralesional approach in the treatment of cancer. For melanoma patients with recurrent or in-transit disease confined to their skin this approach has been used to treat patients for many years, as evidenced by guidelines published by the National Comprehensive Cancer Network (NCCN Guidelines®) defining the standard of care for cancer treatment in the United States. Intralesional injection with BCG and certain immunomodulatory agents, local ablation, topical therapy for superficial lesions and regional radiotherapy are consensus interventions for these patients, while systemic therapy remains an option and participation in a clinical trial is the preferred option. We believe that, in this context, PV-10 is well positioned to show superiority in phase 3 testing as a single agent.
And for those patients who do not have all disease accessible to injection, medical oncologists have stated that using an agent like PV-10 to prime the immune system could be synergistic in combination with a systemic agent. Our patent application on this strategy was published in 2012 and we've been vigorously pursuing this approach. The nonclinical research we first presented at the Society for Immunotherapy of Cancer (SITC) annual meeting that year, together with ongoing translational clinical research on PV-10's mechanism of action we are sponsoring at Moffitt Cancer Center and our own phase 2 data, provide a rationale for combination testing of PV-10. This development track, separate from the phase 3 study, using PV-10 in combination with checkpoint protein inhibitors could present a path forward for patients with significant disease burden not amenable to intralesional injection.
LIVER AND METASTATIC CANCERS
We have recently expanded our exploratory phase 1 study of cancers of the liver to 3 centers (St. Luke's University Health Network, Bethlehem, PA and The Southeastern Center for Digestive Disorders & Pancreatic Cancer, Tampa, FL in addition to Sharp Memorial Hospital, San Diego, CA), and we're evaluating addition of several additional centers to further advance this initial effort. We're working with our investigators to report results from long-term follow-up of our initial patients in coming months. And we're assessing strategies to accelerate transition to phase 2 testing in a randomized controlled trail, either alone or in combination with systemic therapy. Any combination studies in the liver are likely to follow similar development strategies to those outlined above for melanoma and rely on much of the same foundational science.
The current phase 1 study, initially designed solely to establish safety of percutaneous injection of PV-10 into liver tumors (that is, injection through the skin), is providing valuable data crucial for planning such phase 2 development. This trial is open to patients with hepatocellular carcinoma or other cancers metastatic to the liver who have at least one tumor that has either originated in or spread to the liver and are not candidates for surgery or transplant. All patients enrolled in this open-label study receive the same treatment: an interventional radiologist injects PV-10 percutaneously into a single liver tumor. Patients with multiple injectable tumors may later receive further PV-10 to their other tumors. We have received numerous inquiries about this study from researchers as well as patients and their doctors, and refer these to our investigators through the contact information available on the clinicaltrials.gov website.
PH-10 FOR DERMATOLOGICAL TREATMENTS
So far over 220 patients have participated in phase 1 and 2 trials of PH-10. We anticipate posting results from these studies on the clinicaltrials.gov website in the coming months and are encouraged by what has been observed to date. Following the model we've used successfully with PV-10, we're planning a translational clinical study to better understand the possible immunologic mechanism of PH-10 in the skin in relation to psoriasis, eczema and other inflammatory dermatoses. Our investigators are currently evaluating the results of our studies. When their assessments are complete, we will move forward with the necessary further trials and regulatory requirements to bring this compound to patients who need it.
PATENT PORTFOLIO
Provectus has built a solid portfolio of patents to protect our shareholders' value. Among recent additions to this portfolio are: US Patent 8,557,298, "Medicaments for Chemotherapeutic Treatment of Disease," which provides detailed protection of PV-10; US Patent 8,530,675, "Process for the Synthesis of 4,5,6,7-tetrachloro-3',6'-dyhydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one (Rose Bengal) and Related Xanthenes," which details our new process for the manufacture of Rose Bengal and related iodinated xanthenes in high purity; and US Patent Application 2012/0263677, "Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer," which covers methods for treating cancer through combination use of intralesional agents (such as PV-10) with systematic anticancer agents (such as checkpoint protein inhibitors).
SCIENTIFIC CONFERENCES
During the past several months, researchers have presented data on PV-10 in multiple major international conferences. These include annual meetings of the American Society of Clinical Oncology, the European Association of Dermato-Oncology and the American Association for Cancer Research. We believe participation in these conferences is vital to bring a higher profile to PV-10 among oncology researchers. This, in turn, will help us with patient accrual and with further scientific work to support our belief in the efficacy and safety of PV-10.
INTERNATIONAL LICENSING OPPORTUNITIES
Provectus has provided data on a confidential basis to both potential global and geographic partners for both PV-10 for oncology and PH-10 for dermatology via a secure electronic data room. We are encouraged by the number of companies doing due diligence on our technologies. For instance, we recently had a team in India meeting with potential partners and have two teams focused in China working with potential partners there.
Whenever we obtain a Memorandum of Understanding (MOU), definitive agreement or similar indication of interest from a potential partner, we will issue a press release and Form 8-K filing to notify the market. Furthermore, the strategy of the company for the benefit of shareholders is a series of partnerships followed by an acquisition of the company along the lines of Celgene/Abraxis.
We have already signed an advisory agreement with China's TriRiver Capital to help identify distribution and joint venture partners for PV-10 in China. This agreement is intended to enhance our reach into China and will bolster our efforts in developing partnering opportunities in various countries in Asia including China, India and Japan, where we have held numerous detailed discussions with pharmaceutical companies over the last year. We are already seeing the results of efforts to enter into partnerships from the activity in our electronic data room.
MONETIZING PV-10 AND PH-10
The primary financial objective of the Company is to strategically monetize the core value of PV-10 and PH-10 through the various transactions discussed elsewhere in this letter. Ultimately, the Company wants to leverage value creation through the sale of the business or a merger that may include upfront cash, acquirer stock, and/or a contingency value right (CVR) as part of the total consideration. A CVR represents the right for its holder to receive certain defined payments upon the achievement of a specified milestone and would be designed to facilitate potential upside for the Company's shareholders on a post-transaction basis. A CVR could trade on an exchange. The Company is not in discussions regarding the sale of its business and there can be no assurance, however, that the Company will be able to monetize PV-10 or PH-10 in the manner described herein.
SUFFICIENT CAPITAL ON HAND
Our financial position and corporate governance are such that we expect to continue to meet the relevant listing requirements of NYSE MKT. We believe our efforts to obtain regulatory clarity will be helpful to facilitate such transactions with potential partners. Additionally, the existing and forthcoming clinical and nonclinical mechanism of action data for both PV-10 and PH-10 are expected to further aid in both regulatory clarity and transactions with potential partners. The Company's current cash position is sufficient to meet our obligations. In addition, management is returning $8.96 million to the Company as a result of the previously announced settlement of a shareholder derivative lawsuit (subject to a 2:1 credit to the executives, such that total actual repayment by the executives may be $1.12 million per executive) and further enhanced our strength by management's recent exercise of options. In total, we have adequate funds to operate without a further injection of capital through mid-2015.
CORPORATE DEVELOPMENTS
We have changed our Company's name to Provectus Biopharmaceuticals, Inc. because it better communicates to the public and to prospective corporate partners the current and future nature of the Company's business operations and enables us to better implement the Company's business plan. Further, we have reincorporated in Delaware as this gives us more flexibility, clarity and predictability with respect to our corporate governance.
In addition, we have "up-listed" our stock onto the NYSE MKT. Moreover, we have added several important individuals to our Strategic Advisory Board:
Jacob M. Plotsker, MBA, currently Director of US Strategy and Lifecycle Management at Bayer Healthcare. He currently serves on the board of directors of Emisphere Technologies, a publicly traded drug delivery technology company. From 2008 to 2014, he served on the board of directors of Sharsheret, a national 501(c)(3) not-for-profit organization providing support and resources to young women living with breast cancer. He also served as President of Sharsheret from 2009-2012.
Dr. Joseph M. Chalil, MD, MBA, FACHE, Associate Director, Health Science Executives of Boehringer Ingelheim, the world's largest privately held pharmaceutical company. A veteran of the United States Navy Medical Corps, Dr. Chalil is also board certified in healthcare management, and has been awarded Fellowship by the American College of Healthcare Executives. Dr. Chalil is an expert in US Healthcare policy and a strong advocate for patient centered care, and has also served as an advisor to various national political campaigns on healthcare issues.
Brendan O'Brien, MBA, currently VP of Strategic Planning & Analysis for North American Pharmaceuticals at Sanofi, responsible for business planning and strategy development. He has also worked for Smithkline Beecham Pharmaceuticals and for Pfizer.
Further, we have retained Roberti+White to assist in developing a commercialization strategy for PV-10 by implementing a plan to expand our congressional outreach to key Members of Congress, Congressional Committees and Caucuses that address healthcare issues. Roberti+White will also advise us on FDA regulatory issues as they arise and develop action plans in response to such developments. When conditions warrant, Roberti+White will also assist the Company in development of an effective Medicare coverage, coding and payment strategy for its products in development.
We are grateful for the long-term support of our shareholders and their faith in our Company's future. The next several months hold great promise for Provectus, and we look forward to sharing the latest developments with you.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140708 on the Provectus website.
Institutional Ownership 15.34%
from fidelity
it was in July of last year..
http://biz.yahoo.com/e/130724/wddd8-k.html
Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 18, 2013, the registrant held an annual meeting for its shareholders. Following is a brief description of the matters presented to the shareholders and the voting results.
1. Thom Kidrin, Bernard Stolar, and Robert Fireman were duly elected directors of the Company.
The number of votes cast with respect to this matter was as follows:
Nominees for For Withheld
Directors
Thom Kidrin 35,513,901 761,995
Bernard Stolar 36,249,730 25,166
Robert Fireman 36,252,780 22,116
2. The proposal to amend the Company's Certificate of Incorporation to increase its authorized capital to 150,000,000 shares of common stock, par value of $0.001 per share, was approved.
The number of votes cast with respect to this matter was as follows:
FOR AGAINST ABSTAIN
55,784,372 3,258,307 2,530,030
There were no broker held non-voted shares represented at the Meeting with respect to this matter.
3. The proposal to authorize the Company's Board of Directors to implement a reverse split of the Company's outstanding Common Stock, at its discretion, in a ratio ranging from 1:2 to 1:20, was approved.
The number of votes cast with respect to this matter was as follows:
FOR AGAINST ABSTAIN
58,594,656 2,153,266 824,787
There were no broker held non-voted shares represented at the Meeting with respect to this matter.
4. The proposal to ratify the appointment by the Board of Directors of Bongiovanni & Associates, CPA's, as independent public accountants for the Company for the current fiscal year was approved.
The number of votes cast with respect to this matter was as follows:
FOR AGAINST ABSTAIN
61,352,615 71,147 147,947
There were no broker held non-voted shares represented at the Meeting with respect to this matter.
5. The advisory vote approved executive compensation.
The number of votes cast with respect to this matter was as follows:
FOR AGAINST ABSTAIN
33,360,584 2,353,466 560,846
There were 25,296,813 broker held non-voted shares represented at the Meeting with respect to this matter.
6. The advisory vote on the frequency of the advisory vote on executive compensation determined annually.
The number of votes cast with respect to this matter was as follows:
ONE YEAR TWO YEARS THREE YEARS ABSTAIN
33,641,211 3,000 512,933 523,800
There were no broker held non-voted shares represented at the Meeting with respect to this matter.
I believe that its already been voted on, its already been approved.
gota like the volume today.. Id like to see this in the 40s before the markman
agree..
.. had me thinking of selling on the pop this AM.. but reading the 8k really only makes me want to buy more ovno!!
Vorlon is correct.. remember that they are going to be treating all the tumors.. thats huge!!
I purchased more at 3.27.. lowered my average
i like the volume today, stronger hands getting in.. weaker hands and day traders getting out.
Im buying more here
they need to make a co-development deal, I think that's the next news we need to see.
After Hours : 1.17 Up 0.08 (7.34%) 4:27PM EDT
like the VET question at the end of the CC..
looking forward to the liver data
enough $ for P3.. thats very good news!!
wishful thinking
CC not sounding good. No deals to be announced in this call.
this is like a little kid going to his dad after his mom says NO!
how many times have the patents already been validated? 3x, 4x?
how many times can google ask for review? 1,000x? crazy!!
Im just happy I made $ on this already and am pretty much playing for free now.
I agree.. I just bought in again.. thinking there will be licensing news or some sort of collaboration to help with P3 trial.. or maybe even some positive news on the PH-11 front.
Provectus News
Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail Outline of Phase 3 Clinical Trial of PV-10 in Melanoma Treatment
Thursday June 19, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, wishes to remind interested parties that it will hold a conference call today, Thursday, June 19, 2014 at 4:00 p.m. EDT.
Management will discuss the outline of the Company's planned phase 3 study of PV-10 in the treatment of melanoma and developments in the use of PV-10 in other cancer indications including PV-10 in combination as appropriate. It will also review PV-10 data presented in Chicago at ASCO earlier in the month on June 2nd, as well as provide updates on PH-10 and news regarding its use. Management will also discuss its potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions.
The Company has submitted PV-10 phase 2 melanoma study results to www.clinicaltrials.gov and will announce when these are published and become publicly available. In the interim, the Company is providing data presented at ASCO via this link: http://www.pvct.com/publications/ASCO-Poster-2014.pdf, which contains the phase 3 study outline that the Company will discuss on today's conference call. Moffitt Cancer Center data presented at ASCO is expected to be published in a future peer-reviewed journal publication.
Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately 15 minutes before the call. A webcast will also be available at www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until August 19, 2014, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for International callers, and using the Conference ID#13584727.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140619 on the Provectus website.
I put two new low ball bids in .. one at .70 another at .80.. the AF piece should do the trick.
gl all
so do we see an uptick here? anyone think ZTE will settle before the july 8 hearing?
Ex-Parte Preliminary Injunction Remains In Force
NEW YORK - May 30, 2014 - Vringo, Inc. (VRNG), a company engaged in the innovation, development and monetization of intellectual property and mobile technologies, today announced that hearings scheduled to have taken place today before the High Court of Delhi at New Delhi in both of its lawsuits against ZTE in India have been postponed. Vringo expects the injunction against ZTE will remain in force until at least July 8, 2014.
Injunction Against ZTE in India
On January 31, 2014, Vringo and its wholly-owned subsidiary, Vringo Infrastructure, Inc., filed suit against ZTE Corporation, ZTE Telecom India Private Limited, Xu Dejun, the Chief Executive Officer of ZTE Telecom India Private Limited, and IndiaMART InterMESH Limited.
The lawsuit alleges infringement of India Patent No. 200,572, owned by Vringo Infrastructure, Inc., entitled "A Method and a Device for Making a Handover Decision in a Mobile Communication System."
On February 3, 2014, the Court, making a prima facie finding that ZTE infringes the patent in suit, granted an ex-parte preliminary injunction, restraining ZTE and its officers, directors, agents, distributors and customers from importing, selling, offering for sale, advertising, installing, or operating any infringing devices. On March 15, 2014, ZTE appealed.
The Court reserved judgment on the injunction, which Vringo expects will remain in force until the Court holds a status conference, which is scheduled for July 8, 2014.
Motion for Contempt of ZTE
On November 7, 2013, Vringo and its wholly-owned subsidiary, Vringo Infrastructure, Inc., filed suit against ZTE Telecom India Private Limited, ZTE Corporation, and Xu Dejun, Chief Executive Officer of ZTE Telecom India Private Limited.
The lawsuit alleges infringement of India Patent No. 243,980, owned by Vringo Infrastructure, Inc., entitled "Mobile Station Operable with Radio Access Network and a Packet Data Serving Node and a Method for Operating Such Mobile Station."
On November 8, 2013, the Court granted an ex-parte preliminary injunction against ZTE.
On December 12, 2013, in response to ZTE`s appeal of the ex-parte preliminary injunction, the Court ordered ZTE to pay a bond of approximately $800,000 and file an accounting affidavit disclosing the number of CDMA devices sold by its entities in India, revenue derived therefrom, and other supporting documentation.
On February 3, 2014, Vringo filed a motion for contempt of ZTE in which Vringo cites ZTE`s failure to comply with the Court`s order of December 12, 2013.
The hearing on this motion was scheduled for today and is now scheduled for July 8, 2014.
I first got in at .40.. but used the drop to ave down.
I sure would like to see this back in the .40s
smalls
cut and pasted from SA..
In patent infringement cases, a Markman hearing can help outline what is at stake in the trial. It's a pretrial hearing during which a judge examines evidence and the meanings of relevant key words used in a patent claim. This "Claim Construction Hearing" can ultimately put a value on the alleged infringement. The judge also decides on how the language of the patent is to be interpreted, making this pre-trial hearing a seminal part of the lawsuit. Recently, several companies have made the news as their stocks jumped following their Markman hearings. Vringo (VRNG), Parkervision (PRKR), and VirnetX Holding Corp (VHC) have all seen their stock prices move following their Markman hearings, and savvy investors and writers for Seeking Alpha have let us know the time to get in is before the hearing.
The key to maximizing the value from these Markman hearings is to get in before the hearing takes place. In the case of VRNG, the stock began a run up in the weeks before the hearing, trading at $2.72 on May 23, 2012. One day after the ruling, which was favorable to VRNG, the stock closed at $4.36. VHC has seen multiple jumps in its stock from favorable Markman hearings; one of the biggest percentage jumps coming from a hearing early on July 30, 2009, where its stoc kdoubled from $1.48 to $3.00. PRKR traded at $2.43 the day of the hearing on February 20, 2013. The next day the stock closed up considerably, at $4.21 a share, with a market cap of over $340 million. Parkervision has done this without any revenue, and it will not be commercializing a product in the near term.
the markman date has not been set yet,
the parties are to set agree on a date.. next news should be date for markman or settlement
bounces are usually very quick actions .. they follow the quick drops with a quick bounce and a fall back lower
to pay the bounce that occurred on the 27th.. well the way i played it... is buy when the blood was in the water, I tried to purchase at .30, caught it on the way up .48 and then sold at .69
now without news, and big news.. i think we move sideways
just my .02
people really need to do some DD
BTD is something special, that most drugs dont get anyway.. its not an all or none, its just a short cut to being approved.
PV-10 didnt get BTD because they didnt have enough data, FDA agrees that the drug works, but more data was needed for the special BTD designation
bridging study to get the data to resubmit for BTD or a Phase III will be needed. yes its more time, more $ but the drug works
people need to do their DD and know what kind of time frame were looking at
I hope the mgt learns a hard lesson from this and moves quickly on the other trials (PH-10 etc).
my .02
smalls
Tom,
Im thinking the same thing, on the drop down to .30 I tried to play the bounce, I made a quick 45% but it was a large score, moved my 2.46 ave down to roughly .82 .. still down a little overall on PVCT but I will play the sink bid game some more
seams like my fav stocks are also the most shorted
good luck
smalls
buying at open looking for the dead cat bounce is smart, i just cut my losses on this stock by 80% or more.
i did, bought at .51 looking to sell some for a quick flip
no.. under review by the NYSE.. total bs.. guess I aint getting any work done today
lol, cool thanks.. I have a meeting at 10:30 CST so Im sure it will be released at 10:31
why do these things take so long?
wouldn't they have the press release ready?
Im looking to buy today.. I missed the chance to add earlier, but there is still hope.
Added this morning.. looking like a nice gift.
long and strong
Judicial Preferences
Judge Lioi believes that the Case Management Conference (CMC) is of extraordinary importance. She expects counsel to be prepared with the factual predicate from the standpoint of counsel's client. Judge Lioi expects the client to be present; where the client is a corporate entity, she expects a person to be present who has the greatest knowledge of the relevant facts. Judge Lioi specifically tailors the Case Management Plan to the particular case based on the information supplied at the CMC by counsel and parties. In addition, during the CMC, Judge Lioi will seriously explore settlement possibilities, with an eye toward resolving the case as early as possible. Therefore, persons with actual settlement authority are also required to attend the CMC.
quiet day today.. good day to pick up some more up
once we get a markman date, this should pop nicely.
I am sure glade I didnt over react and sell at .06 on the news.. only wish i had the balls to add at that time.
10
In this case, Worlds alleges continued infringement through the lives of the Patents-In-Suit. D. 32. Indeed, nothing about the Court’s order prevents Worlds from asserting infringement from the date of the certificate going forward. E.I. Du Pont De Nemours & Co. v. MacDermid Printing Solutions, L.L.C., 525 F.3d 1353, 1362 (Fed. Cir. 2008) (noting that “each act of infringement gives rise to a separate cause of action” and concluding that, while a certificate of correction will not apply if it issues after the “cause of action arose,” it can apply to future infringing conduct). In light of the foregoing, the Court declines to enter judgment in Defendants’ favor at this time. Instead, the Court ORDERS the parties to meet and confer to discuss whether the appropriate course of action is for the Court to dismiss the instant action (without preventing Worlds from commencing a new action alleging infringement from the date of the certificates going forward), or merely confine this decision to infringement allegedly occurring from the dates the patents issued through the lives of the Patents-In-Suit. The parties shall file a joint statement, not exceeding more than five (5) pages, outlining their respective positions with the Court no later than March 27, 2014.
guess we need news from WDDD to see if they will be able to correct the patents and re-submit the lawsuit?
Im not selling for .08.. gamble is win big or go home with nothing
Im back in on todays drop!! was waiting for a good time to jump back in.
good luck longs!!
it was down today because I added yesterday. lol
added more today at 8.61
good luck longs!!